CJC-1295 No DAC + Ipamorelin

The concept of the CJC-1295 + Ipamorelin blend stems from parallel developments in peptide research aimed at exploring growth hormone modulation. CJC-1295, a synthetic analog of growth hormone–releasing hormone (GHRH), was developed in the early 2000s to extend the half-life and activity of natural GHRH fragments for research into growth hormone and IGF-1 pathways; that development work produced the DAC-bearing molecule, which the no-DAC constituent supplied here does not contain. Meanwhile, Ipamorelin—a selective ghrelin receptor agonist—emerged from studies in the 1990s investigating ghrelin mimetics and their ability to stimulate growth hormone release with minimal off-target hormonal effects. Together, these peptides became of interest for laboratory research into how GHRH receptor signaling and ghrelin receptor (GHS-R1a) signaling interact to shape pulsatile growth hormone secretion and downstream IGF-1 pathway activity.

CAS #: 446036-97-1
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.9 g/mol
PubChem ID: 91976842

CAS #: 170851-70-4
Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.9 g/mol
PubChem ID: 9831659

CJC-1295 and Ipamorelin have each been examined separately in endocrine, signaling, experimental, and systemic models, with research exploring their influence on somatotroph axis pathways, downstream cascades, pathway activity, and molecular viability. Studies have examined their signaling kinetics, receptor selectivity, and downstream IGF-1 pathway activity in preclinical and experimental settings.

Key Areas of Research:

• Endocrine: Somatotroph axis, signaling, cascades
• Signaling: Lipid pathways, dynamics, markers
• Molecular: Proliferation, remodeling, viability
• Systemic: Vascular, IGF-1 axis, pathway activity

These findings relate to the individual constituents; the studies cited on this page did not examine the finished CJC-1295 + Ipamorelin blend.

Campbell R.M. et al., Peptides, 1994

Raun K. et al., European Journal of Endocrinology, 1998

Campbell R.M. et al. (1994). Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides, 15(3):489–95. PubMed ID 7937325.

Bongers J. et al. (1992). Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta, 1122(2):147–53. PubMed ID 1353684.

Raun K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 139(5):552–61. PubMed ID 9849822.